Gelonghui, March 11 | Weiss Healthcare (688580.SH) said on the investor interactive platform, according to the World Neuromodulation Society's definition of “neuroregulation” — that is, in the field of combining technology, medical treatment, and bioengineering technology, signals are transmitted to neurons or neural networks in the central, peripheral, and neighboring or remote parts of the autonomic nervous system through electrical or chemical effects, thereby improving patients' quality of life or improving body function. The company currently has a long-term business layout in the field of non-implantable neuromodulation. The company's second-generation transcranial magnetic stimulator has many competitive advantages such as multiple channels, free combination of depth and depth, and special coils, and can provide cutting-edge non-invasive neuromodulation treatment methods in the field of psychosocial psychology and nerve conduction. Currently, it includes various models for mental rehabilitation, neurological rehabilitation, children, automatic navigation, etc. Since the launch of second-generation products, the business scale and clinical penetration rate have grown rapidly and received good feedback from the market. Meanwhile, in late August '23, the company successfully launched a “transcranial electrical stimulator” cooperation. It will further collaborate to further promote the application and development of transcranial magnetic stimulation and transcranial electrical stimulation technology in the field of neuroscience, and continuously improve the company's technical level in the field of neuroregulation. Currently, the company has no implantable neuromodulation products being developed or sold. In the future, it will continue to enrich its business layout in line with development trends and future directions in the field of neuromodulation.